Allergan Plc's Revenue in the fiscal year 2019 $ 16,088.90 millions
Allergan Plc's Revenue in the fiscal year 2018 $ 15,787.40 millions
Allergan Plc's Revenue in the fiscal year 2017 $ 15,940.70 millions
Allergan Plc's Revenue in the fiscal year 2016 $ 14,570.60 millions
Allergan Plc's Revenue in the fiscal year 2015 $ 15,071.00 millions
AGN Revenue first quarter 2020 Y/Y Growth Comment
Allergan plc reported Revenue growth of 0.2% year on year in the first quarter 2020, to $ 3,604.40 millions, this is lower than Allergan Plc's recent average Revenue increase of 17.86%.
Looking into first quarter 2020 results within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue growth. While Allergan Plc' s Revenue increase of 0.2% ranks overall at the positon no. 1835 in the first quarter 2020.
Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020
Allergan Plc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
78.29 %
2.47 %
-40.77 %
(Dec 31 2013)
AGN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Allergan Plc disclosed fall in Revenue from the fourth quarter by -17.16% to $ 3,604.40 millions, from $ 4,351.00 millions achived in the previous reporting period.
But that's not important problem, as Allergan Plc's Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 161 other companies have achieved higher Revenue quarter on quarter growth. While Allergan Plc's Revenue growth quarter on quarter, overall rank is 2812.
In the I. Quarter 2020 Allergan Plc disclosed fall in Revenue from the fourth quarter by -17.16% to $ 3,604.40 millions, from $ 4,351.00 millions achived in the previous reporting period.
But that's not important problem, as Allergan Plc's Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 161 other companies have achieved higher Revenue quarter on quarter growth. While Allergan Plc's Revenue growth quarter on quarter, overall rank is 2812.
Allergan Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2020)
12 Months Ending (Dec 31 2019)
12 Months Ending (Sep 30 2019)
12 Months Ending (Jun 30 2019)
12 Months Ending (Mar 31 2019)
Cumulative Revenue 12 Months Ending
$ 16,096.20
$ 16,088.90
$ 15,817.60
$ 15,678.30
$ 15,712.40
Y / Y Revenue Growth (TTM)
2.44 %
1.91 %
-1.35 %
-2.96 %
-2.04 %
Year on Year Revenue Growth Overall
Ranking
# 2336
# 1468
# 1929
# 2665
# 2451
Seqeuential Revenue Change (TTM)
0.05 %
1.72 %
0.89 %
-0.22 %
-0.48 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2163
# 1625
# 1670
# 2371
# 2057
Cumulative Revenue growth Comment
Although Allergan Plc's Annual Revenue growth year on year were below company's average 17.69% , Revenue announced in the Mar 31 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.44% year on year, from 1.91% in Dec 31 2019.
In the Healthcare sector 328 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1468 to 2336.
Although Allergan Plc's Annual Revenue growth year on year were below company's average 17.69% , Revenue announced in the Mar 31 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.44% year on year, from 1.91% in Dec 31 2019.
In the Healthcare sector 328 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1468 to 2336.
About Allergan Plc Revenue Growth Rates (AGN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.20%